Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Scinai Immunotherapeutics Ltd. from 31 Dec 2021 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Scinai Immunotherapeutics Ltd. annual and quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Dec 2021 to 31 Dec 2024.
  • Scinai Immunotherapeutics Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Jun 2023 was $3,611,000.
  • Scinai Immunotherapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $4,796,000.
  • Scinai Immunotherapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $6,233,000, a 8.4% decline from 2022.
  • Scinai Immunotherapeutics Ltd. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $5,748,000, a 30% increase from 2021.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)

Scinai Immunotherapeutics Ltd. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,796,000 +$11,029,000 01 Jan 2024 31 Dec 2024 20-F 07 May 2025 2024 FY
2023 $6,233,000 -$485,000 -8.4% 01 Jan 2023 31 Dec 2023 20-F 07 May 2025 2024 FY
2022 $5,748,000 +$2,419,000 +30% 01 Jan 2022 31 Dec 2022 20-F 07 May 2025 2024 FY
2021 $8,167,000 01 Jan 2021 31 Dec 2021 20-F 15 May 2024 2023 FY

Scinai Immunotherapeutics Ltd. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $3,611,000 +$6,607,000 01 Apr 2023 30 Jun 2023 6-K/A 18 Aug 2023 2023 Q2
Q1 2023 $3,399,000 -$890,000 -35% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q2 2022 $2,996,000 01 Apr 2022 30 Jun 2022 6-K/A 18 Aug 2023 2023 Q2
Q1 2022 $2,509,000 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.